<DOC>
	<DOCNO>NCT01205152</DOCNO>
	<brief_summary>This clinical trial study long term safety efficacy asfotase alfa infant young child infantile onset HPP complete ENB-002-08 study . Partial funding study provide Office Orphan Product Development ( OOPD ) .</brief_summary>
	<brief_title>Extension Study Protocol ENB-002-08 - Study Asfotase Alfa Infants Young Children With Hypophosphatasia ( HPP )</brief_title>
	<detailed_description>Asfotase Alfa formerly refer ENB-0040 Hypophosphatasia ( HPP ) life-threatening , genetic , ultra-rare metabolic disease characterize defective bone mineralization impair phosphate calcium regulation lead progressive damage multiple vital organ , include destruction deformity bone , profound muscle weakness , seizure , impair renal function , respiratory failure . There approve disease-modifying treatment patient disease . There also limit data available natural course disease time , particularly patient juvenile-onset form .</detailed_description>
	<mesh_term>Hypophosphatasia</mesh_term>
	<criteria>Inclusion Criteria Patient complete participation ENB00208 Written inform consent parent legal guardian prior study procedure perform Parent legal guardian willing comply study requirement Exclusion Criteria History sensitivity constituent study drug Clinically significant disease precludes study participation Enrollment study involve investigational drug , device , treatment HPP ( e.g. , bone marrow transplantation )</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>42 Months</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Hypophosphatasia</keyword>
	<keyword>HPP</keyword>
	<keyword>Bone Disease</keyword>
	<keyword>Soft Bones</keyword>
	<keyword>Low Alkaline Phosphatase</keyword>
	<keyword>genetic metabolic disorder</keyword>
	<keyword>alkaline phosphatase</keyword>
	<keyword>tissue non-specific alkaline phosphatase</keyword>
	<keyword>rickets</keyword>
	<keyword>osteomalacia</keyword>
</DOC>